From the Journals

GIMEMA ALL2820: Chemotherapy-Free Regimen Studied in Front-Line Setting

As front-line therapy, a chemotherapy-free regimen combining the tyrosine kinase inhibitor (TKI) ponatinib and the bispecific T-cell engager blinatumomab significantly outperformed standard treatment ...

Share

  • 1

    GIMEMA ALL2820 trial compares ponatinib/blinatumomab vs. imatinib/chemo in Ph-positive ALL.

  • 2

    Ponatinib/blinatumomab demonstrates improved event-free survival (90%).

  • 3

    Complete hematologic response: 94.3% for experimental vs. 79.4% control.

  • 4

    MRD-negative status achieved by 70.9% in experimental arm.

  • 5

    Highlights reduced secondary malignancy risk.

  • 6

    Indicates shift toward chemotherapy-free regimens in frontline treatment.

  • 7

    Further studies needed on CNS relapse risk and TKI balancing.

Original Source(s)

GIMEMA ALL2820: Chemotherapy-Free Regimen Studied in Front-Line Setting

As front-line therapy, a chemotherapy-free regimen combining the tyrosine kinase inhibitor (TKI) ponatinib and the bispecific T-cell engager blinatumomab significantly outperformed standard treatment ...

  • by Caroline Helwick

  • March 4, 2026

  • 8 min

Related Content

Fellowship Training That Goes Where You Go

As Chief Fellow Giuliana Berardi, MD, a third-year Hematology/Oncology Fellow at Fox Chase Cancer Center, reflected on her medical training, she noted the steep learning curve that accompanied each new level of medical training.

  • by

  • February 16, 2026

  • 2 min
Delivering Big Ideas from ASH 2025

At Fox Chase Cancer Center and Temple University Hospital, it’s “in the blood” of our residents and Fellows to develop innovative scientific ideas that significantly affect the way blood diseases are diagnosed and treated. Here is the latest from ASH 2025:

  • by

  • February 17, 2026

  • 1 min
Bone Marrow Transplant: How Keck Medicine of USC Is Excelling in Survival Outcomes

Preet M. Chaudhary, MD, PhD, discusses the repeat ranking of the USC Norris Blood and Marrow Transplant and Cell Therapy Program as one of the nation’s elite allogeneic transplant programs with the highest survival outcomes.

  • by

  • February 13, 2026

  • 12 min